| 中文名 | Licogliflozin |
|---|---|
| 英文名 | Licogliflozin |
| 中文别名 |
(2S,3R,4R,5S,6R)-2-(3-((2,3-二氢苯并[B] [1,4]DIOXIN-6-基)甲基)-4-乙基苯基)-6-(羟甲基)四氢-2H-吡喃-3,4,5-三醇
(2S,3R,4R,5S,6R)-2-(3-((2,3-二氢苯并[B][1,4]二恶英-6-基)甲基)-4-乙基苯基)-6-(羟甲基) )四氢-2H-吡喃-3,4,5-三醇 |
| 英文别名 |
(2S,3R,4R,5S,6R)-2-[3-(2,3-DIHYDRO-BENZO[1,4]DIOXIN-6-YLMETHYL)-4-ETHYL-PHENYL]-6-HYDROXYMETHYL-TETR
LIK066 D-Glucitol, 1,5-anhydro-1-C-[3-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-ethylphenyl]-, (1S) SGLT,LIK 066,LIK-066,Licogliflozin,inhibit,Sodium-dendent glucose cotransporters,Inhibitor Licogliflozin (LIK066) (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol licogliflozin bis(prolinate) (2S,3R,4R,5S,6R)-2-(3-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| 描述 | Licogliflozin 是一种钠-葡萄糖协同转运蛋白 (SGLT1 和 SGLT2) 抑制剂。 |
|---|---|
| 相关类别 | |
| 靶点 |
SGLT1, SGLT2[1] |
| 体外研究 | Licogliflozin(LIK066)是一种用于非酒精性脂肪性肝炎(NASH)的非抗纤维化治疗药物。 |
| 参考文献 |
| 分子式 | C23H28O7 |
|---|---|
| 分子量 | 416.46 |
| 储存条件 | 2-8℃ |